Scribe Therapeutics Submits IPO Filing for CRISPR-Based PCSK9-Targeting Epigenetic Therapy

▲9June 4-5   CBI Biopharmaceutical Innovation Expo Scan the QR Code to Register

Note:This article does not constitute any investment advice or recommendations; please refer to official/company announcements for authoritative information;This article is intended solely for the introduction of drugs related to medical health and does not constitute a recommendation for treatment plans (if any); it does not represent the platform's position.Any article reprints require authorization.

PharmaCircle DataMonitoring shows: On July 2, 2026, Scribe Therapeutics, Inc., an Australian company, filed its S-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on July 2, planning to conduct an initial public offering (IPO) of common stock on the Nasdaq Global Market under the ticker symbol SCTX, with a maximum total fundraising target of $75 million.

The company is a clinical-stage CRISPR genomic and epigenomic editing biotechnology enterprise focused on cardiovascular and metabolic diseases.

The Company’s core, self-developed clinical candidate is STX-1150, an in vivo therapy leveraging the Company’s proprietary ELXR epigenetic editing platform (Epigenetic Long-Term X-Repressor), inHepatocytesimplemented inLong-acting Transcriptional Silencing of the PCSK9 Gene; As of the date of submission of this document,STX-1150 Has Entered Phase I Clinical Trials in Humans for Hypercholesterolemia。

None of the securities proposed for issuance or sale in this initial public offering (IPO) carry any obligation to pay royalties. Separately, the company holds an upstream CRISPR technology licensing and collaboration agreement under which Scribe is entitled to receive tiered commercialization royalties from its partner, Eli Lilly and Company (“Lilly”), and its wholly-owned subsidiary, Prevail Therapeutics.

Pursuant to the aforementioned BD/technology licensing terms, Scribe shall permanently retain the right to collect royalties on all CRISPR therapeutic products developed and commercialized by Lilly and Prevail using Scribe’s engineered CRISPR editing tools.

In China, companies engaged in similar therapies include: Epigenic, etc.A company founded by Zhou Changyang of the Center for Excellence in Brain Science and Intelligence Technology (Institute of Neuroscience), Chinese Academy of Sciences.

https://cn.epigenictx.com/innovation/pipeline

Attachment, Share:

Follow the "YaoRongQuan" WeChat Official Account to receive updates on new drug information. For study and sharing purposes only; not intended as investment advice or recommendations!

References:

PharmCube Data;

FDA/EMA；

NMPA；

https://www.sec.gov/Archives/edgar/data；

https://www.businesswire.com；

https://lifescivoice.com；

https://www.globenewswire.com/n

ews-release；

https://www.businesswire.com/news/home；

https://www.ion.ac.cn/xwen/kyjz/2025/202509/t20250930_7983413.html；

https://www.businesswire.com/news/home/20260528472123/en/Scribe-Therapeutics-Presents-Late-Breaking-Preclinical-Data-Supporting-STX-1150-a-Clinical-Stage-Epigenetic-Silencing-Therapy-Designed-to-Achieve-Years-of-LDL-C-Lowering-After-a-Single-Dose；

Wait.